Dublin, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The "Biosimilar Interleukins Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
The global biosimilar interleukins market is expected to grow from $1.03 billion in 2020 to $1.33 billion in 2021 at a compound annual growth rate (CAGR) of 29.1%. The market is expected to reach $4.94 billion in 2025 at a CAGR of 39%.
Major players in the biosimilar interleukins market are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech, and Sunshine Guojian Pharmaceutical.
The biosimilar interleukins market consists of sales of interleukin biosimilars generated by the establishments that manufacture interleukin biosimilars that are used to treat various autoimmune diseases. Interleukin is a substance derived from white blood cells that enhances infection activity and is used to fight certain types of cancer.
The biosimilar interleukins market covered in this report is segmented by type into IL-17, IL-23, IL-1, IL-5, IL-6, others. It is also segmented by application into psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease (IBD), others and by distribution channel into hospital pharmacies, online pharmacies, retail pharmacies, clinics, research institutes.
The regulatory framework around the approval of interleukin biosimilars hampers the growth of the market. Biosimilars are manufactured with changes in the manufacturing process impacting the physicochemical and functional properties of a biologic drug and it is impractical to create an exact copy of the biologic drug.
This compels the manufacturers to demonstrate biosimilarity between interleukin biosimilar and the biologic drug to prove that there are no clinically meaningful differences.
This calls for extensive comparative analytical, nonclinical, and clinical assessments to get approval from the medical authorities, thereby, increasing the cost of the approval process and restraining the growth of the market.
The increasing prevalence of autoimmune diseases such as psoriasis and rheumatoid arthritis is expected to boost the growth of the interleukin biosimilars market in the forecast period. Autoimmune disorders are conditions in which the immune cells cannot distinguish healthy cells from potentially dangerous antibodies. Biologic drugs such as anti-interleukin antibodies have shown significant clinical benefit in regulating the cells, and in directing proliferation, activation, and migration of the cells.
According to the British Society for Immunology report 2018, many autoimmune disorders showed a year-on-year increase in incidence at rates between 3% and 9%. In the US, there were 7.4 million people affected with psoriasis in 2017 and this number is ever increasing.
Therefore, the increasing prevalence of autoimmune diseases is increasing the demand for the biosimilar interleukins market and is expected to drive the growth of the market.
Key Topics Covered:
1. Executive Summary
2. Biosimilar Interleukins Market Characteristics
3. Biosimilar Interleukins Market Trends and Strategies
4. Impact Of COVID-19 On Biosimilar Interleukins
5. Biosimilar Interleukins Market Size and Growth
5.1. Global Biosimilar Interleukins Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Biosimilar Interleukins Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market
6. Biosimilar Interleukins Market Segmentation
6.1. Global Biosimilar Interleukins Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
6.2. Global Biosimilar Interleukins Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
Inflammatory Bowel Disease (IBD)
6.3. Global Biosimilar Interleukins Market, Segmentation by Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7. Biosimilar Interleukins Market Regional and Country Analysis
7.1. Global Biosimilar Interleukins Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Biosimilar Interleukins Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
Sunshine Guojian Pharmaceutical
For more information about this report visit https://www.researchandmarkets.com/r/wek7q8
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900